Diagonal Therapeutics
PrivateLast Round
Series B
Jan 8, 2026
Total Funding Raised
$253M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Diagonal Therapeutics operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a Series B round in January 2026.
Diagonal Therapeutics is a biotechnology company that discovers and develops agonist antibodies using a proprietary platform to address the root causes of severe diseases such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diagonal Therapeutics Comparables
Compare Diagonal Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vaderis Therapeutics | 81% | |
| Tectonic Therapeutic | 79% | |
| AltruBio | 71% |
For institutional investors. Book with your work email.
Diagonal Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 8, 2026 | ||||
| Series A | Apr 3, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Diagonal Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| Janus Henderson Group | Series B |
| RA Capital Advisors | Series A |
| Balyasny Asset Management L.P. | Series B |
| RA Capital Management | Series A, Series B |
| VF Partners | Series A |
| Deep Track Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2026
Grew 23% QoQ from 31 to 38 employees.
- Aug 20, 2026
Monthly visitors increased 66% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 29, 2026
Diagonal Therapeutics, Inc. appoints Jeremy Bender, Ph.D., M.B.A., as Chair of its Board of Directors in Massachusetts on Oct 29th '26, succeeding Michael Gladstone, who continues to serve on the Board.
- is_developingAug 12, 2026
As of Aug 12th '26, Diagonal Therapeutics, Inc. tests its bispecific antibody, DIAG723, in the Phase I/II DIAMOND trial (NCT07623525) to restore normal ALK1 signalling and potentially modify disease in hereditary haemorrhagic telangiectasia type 2.
For institutional investors. Book with your work email.
Diagonal Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Diagonal Therapeutics's valuation, stock price, and market status.
Is Diagonal Therapeutics a public or private company?
Diagonal Therapeutics is a private company.
What is the current stock price of Diagonal Therapeutics?
Diagonal Therapeutics is a private company, so its shares have no public market price. Caplight tracks Diagonal Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Diagonal Therapeutics worth (valuation)?
Valuation information for Diagonal Therapeutics is not publicly available.
Can I buy Diagonal Therapeutics stock?
Diagonal Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Diagonal Therapeutics's last funding round?
Diagonal Therapeutics's most recent funding round was Series B on January 8, 2026.
Who are the main investors in Diagonal Therapeutics?
Key investors in Diagonal Therapeutics include Janus Henderson Group, VF Partners, BVF Partners L.P., Sanofi Ventures, Atlas Venture.
Will Diagonal Therapeutics IPO soon?
No public IPO plans have been announced for Diagonal Therapeutics.
How can I track Diagonal Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Diagonal Therapeutics's shares on secondary markets.